Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic targeting of KMT2D mutant lung squamous cell carcinoma through RTK-RAS signaling inhibition

Therapeutic targeting of KMT2D mutant lung squamous cell carcinoma through RTK-RAS signaling inhibition

US Patent 12336988 · Granted Jun 24, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method for enabling a terminal to access a base station, and base station, termi2025
Method for synthesizing intermetallic alloy nanoparticles2025
Polyurethane based medical articles2025
Optical module2025
Active snubbers for solid state circuit breakers to improve switch voltage utili2025
Methods of use of emulsion formulations of aprepitant2025
APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositio2025
Test card2024
Solid-state circuit breaker based on a wireless coupling and resonant circuit fo2024
Test card2024
Method for synthesizing 2H/1T′ TMD heterophase junctions and a device based on t2024
Test card2024